LMC Healthcare & Centricity Researches own Drs. Ronnie Aronson, Harpreet Bajaj, and Ruth Brown‘s manuscript titled “SGLT2 inhibitors and incretin agents: associations with alanine aminotransferase activity in type 2 diabetes” has been accepted to appear in the Diabetes & Metabolism Journal.


What is current knowledge?
– Non-alcoholic fatty liver disease (NAFLD) associated with type 2 diabetes (T2D) is a growing epidemic.

– Thiazolidinediones are the only class of diabetes therapies with proven beneficial liver effects.

– The effect of newer diabetes therapies on markers of NAFLD is uncertain.

What is new here?
– SGLT2 inhibitors were associated with significantly greater reductions in ALT compared to incretin therapies.

– This association for SGLT2 inhibitors, but not for incretin medications, was independent of weight and A1c change. A similar association between SGLT2 inhibitors and ALT change persisted in a propensity score weighted analysis that balanced baseline characteristics between treatment groups.

– A significant dose-response relationship was observed for ALT reduction with SGLT2 inhibitors at higher baseline ALT levels.


Abstract – Aim

The impact of new classes of glucose lowering medications on markers of non-alcoholic fatty liver disease (NAFLD) associated with type 2 diabetes (T2D) have been inconsistent in their magnitude and independence. This large retrospective study investigates changes in alanine aminotransferase (ALT) levels among subjects initiated on newer classes of T2D medications in comparison to a reference control group.


To follow up with the entire manuscript, visit HERE.